Palmitoylethanolamide (micronized PEA)
Palmitoylethanolamide (PEA / Micronized PEA) · also known as PEA, Palmitoylethanolamide, Micronized PEA
Palmitoylethanolamide (PEA) is an endogenous human lipid that can activate the PPAR-α receptor. In animal models, it can reduce inflammation and regulate mast cell infiltration, but mast cell and NF-κB-related mechanisms have not been confirmed in humans.
Clinical uses and human evidence
Osteoarthritis pain
Peripheral neuropathy (numbness and tingling)
Studies (2)
- Cocito 2014 · Pain Res Treat · Open-label study · n=30 — Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain
- Pickering 2022 · Inflammopharmacology · RCT · n=70 — A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
Sleep quality
Studies (2)
- Rao 2021 · Sleep Sci Pract · RCT · n=125 — Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study
- Pickering 2022 · Inflammopharmacology · RCT · n=70 — A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
Mechanisms of action
Mast cell membrane stabilization and degranulation blockade
Mast cell effects come mainly from animal and cell studies. In rat studies, oral PEA can reduce inflammation and lower mast cell infiltration in inflamed tissue. Human pain trials cannot prove this mechanism, and how strongly routine oral doses act on target tissue in humans is unclear.
Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription
PEA can activate PPAR-α. In mice lacking PPAR-α, some of its anti-inflammatory effects were lost. In inflamed rat tissue, NF-κB signaling also decreased somewhat. Whether routine oral doses can reach enough receptor occupancy in target tissue to produce measurable NF-κB inhibition has not been confirmed in humans.